Association of urine osmolality trajectory during tolvaptan treatment with renal prognosis in autosomal dominant polycystic kidney disease

Introduction Tolvaptan has been approved for the treatment of autosomal dominant polycystic kidney disease (ADPKD). Nevertheless, an established therapeutic marker remains elusive. We evaluated the association between long-term urine osmolality trajectories and treatment outcomes in ADPKD patients treated with tolvaptan. Methods We included ADPKD patients who started tolvaptan between 2014 and 2022 and who had at least three years of follow-up. Patients were categorized into two groups according to changes in urine osmolality from baseline using a latent class trajectory model. We evaluated the associations of urine osmolality trajectories with kidney growth rate and eGFR decline. Results The analysis examined 57 patients, 49% female, with mean age of 51.7 ± 13.3 years, and mean total kidney volume of 1585.8 ± 1075.4 mL. Latent class trajectory analysis of urine osmolality over three years identified two classes: a larger-decrease class (class 1) and a milder-decrease class (class 2). Patients in class 1 had a significantly slower rate of eGFR decline than those in class 2 (-1.89 ± 0.15 vs. -2.70 ± 0.12 mL/min/1.73m2 per year, p<0.05). Multivariable regression analysis also revealed that class 1 was associated with a slower rate of eGFR decline. No significant association was observed between urine osmolality trajectory and kidney growth rate. Conclusion A larger decrease in urine osmolality, as identified by an unsupervised trajectory model, was associated with a slower rate of eGFR decline but not with the kidney growth rate. Urine osmolality trajectory may be a potential marker of treatment response to tolvaptan in ADPKD patients.

Authors

Publication Details

Journal
The Nephron journals/Nephron journals
Published
2026-11-19
DOI
https://doi.org/10.1159/nef/adtag020
Primary Topic
Genetic and Kidney Cyst Diseases
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Association of urine osmolality trajectory during tolvaptan treatment with renal prognosis in autosomal dominant polycystic kidney disease

Kenjiro Honda, Masaomi Nangaku, Ryohei Horie, Ryo Matsuura et al.
The Nephron journals/Nephron journals
Genetic and Kidney Cyst Diseases
article

Association of urine osmolality trajectory during tolvaptan treatment with renal prognosis in autosomal dominant polycystic kidney disease

Kenjiro Honda, Masaomi Nangaku, Ryohei Horie, Ryo Matsuura, Yoshifumi Hamasaki, Marie Morota, Kent Doi
article en

Abstract

Introduction Tolvaptan has been approved for the treatment of autosomal dominant polycystic kidney disease (ADPKD). Nevertheless, an established therapeutic marker remains elusive. We evaluated the association between long-term urine osmolality trajectories and treatment outcomes in ADPKD patients treated with tolvaptan. Methods We included ADPKD patients who started tolvaptan between 2014 and 2022 and who had at least three years of follow-up. Patients were categorized into two groups according to changes in urine osmolality from baseline using a latent class trajectory model. We evaluated the associations of urine osmolality trajectories with kidney growth rate and eGFR decline. Results The analysis examined 57 patients, 49% female, with mean age of 51.7 ± 13.3 years, and mean total kidney volume of 1585.8 ± 1075.4 mL. Latent class trajectory analysis of urine osmolality over three years identified two classes: a larger-decrease class (class 1) and a milder-decrease class (class 2). Patients in class 1 had a significantly slower rate of eGFR decline than those in class 2 (-1.89 ± 0.15 vs. -2.70 ± 0.12 mL/min/1.73m2 per year, p<0.05). Multivariable regression analysis also revealed that class 1 was associated with a slower rate of eGFR decline. No significant association was observed between urine osmolality trajectory and kidney growth rate. Conclusion A larger decrease in urine osmolality, as identified by an unsupervised trajectory model, was associated with a slower rate of eGFR decline but not with the kidney growth rate. Urine osmolality trajectory may be a potential marker of treatment response to tolvaptan in ADPKD patients.

The Nephron journals/Nephron journals
Genetic and Kidney Cyst Diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon